AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Company Description
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
The company's BD Medical segment offers peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems.
Its BD Life Sciences segment provides specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers.
The company's BD Interventional segment offers hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products.
The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Country | United States |
IPO Date | Feb 21, 1973 |
Industry | Medical - Instruments & Supplies |
Sector | Healthcare |
Employees | 70,000 |
CEO | Thomas E. Polen Jr. |
Contact Details
Address: 1 Becton Drive Franklin Lakes, New Jersey United States | |
Website | https://www.bd.com |
Stock Details
Ticker Symbol | BDX |
Exchange | NYSE |
Fiscal Year | October - September |
Reporting Currency | USD |
CIK Code | 0000010795 |
CUSIP Number | 075887109 |
ISIN Number | US0758871091 |
Employer ID | 22-0760120 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Thomas E. Polen Jr. | President, Chief Executive Officer & Chairman |
Denise Russell Fleming | Executive Vice President of Technology & Global Services and Chief Information Officer |
Elizabeth McCombs | Executive Vice President & Chief Technology Officer |
Shana Carol Neal | Executive Vice President & Chief People Officer |
Claudia Curtis | Senior Vice President, Chief Ethics & Compliance Officer |
Dr. Joseph M. Smith F.A.C.C, M.D., Ph.D. | Senior Vice President, Chief Scientific Officer & Co-Chair of Scientific Advisory Board |
Greg Rodetis | Head of Investor Relations |
Michael Garrison | Executive Vice President & President of Medical segment |
Michelle Quinn | Executive Vice President & General Counsel |
Thomas J. Spoerel | Senior Vice President, Controller & Chief Accounting Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Dec 20, 2024 | 4 | Filing |
Dec 19, 2024 | ARS | Filing |
Dec 19, 2024 | DEFA14A | Filing |
Dec 19, 2024 | DEF 14A | Filing |
Dec 10, 2024 | 4 | Filing |
Dec 10, 2024 | 4 | Filing |
Dec 06, 2024 | 4 | Filing |
Dec 03, 2024 | 4/A | [Amend] Filing |
Dec 03, 2024 | 4/A | [Amend] Filing |
Nov 29, 2024 | 4 | Filing |